Targeted prevention of coronary artery disease: Pharmacological considerations in multimodality treatment

Cardiology (Switzerland)

Volumn 87, Issue 6, 1996, Pages 469-475

  Shviro, Iris ^a   Leitersdorf, Eran ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cholesterol; Cyclosporine; Familial hypercholesterolemia; Fibric acid analogues; HMG CoA reductase inhibitors; Hyperlipidemia; Transplantation

Indexed keywords

CHOLESTEROL; CYCLOSPORIN A; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; ATHEROSCLEROSIS; BEHAVIOR MODIFICATION; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FAMILIAL HYPERCHOLESTEROLEMIA; HEART INFARCTION SIZE; HEART MUSCLE CONTRACTILITY; HEMOSTASIS; HYPERCHOLESTEROLEMIA; HYPERTENSION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RISK FACTOR;

EID: 0029743021     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000177140     Document Type: Article

References (38)

1. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1994:269:3015-3023.
2. Prevention of coronary heart disease. Scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by the international task force for prevention of coronary' heart disease. Nat Metab Cardiovasc Dis 1992:2:113-156.
3. Pierce R. Wysowski DK. Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gcmfibrozil combination therapy. JAMA 1990: 264:71-75.
4. East C. Bilheimer DW. Grundy SM: Combination therapy for familial combined hyperlipidemia. Ann Intern Med 1988;109:25-32.
5. Illingworth R. Bacon S: Influence of lovastalin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia. Circulation 1989:79:590-596.
6. Grag A. Grundy SM: Gemfibrozil alone and in combination with lovastatin for treatment of hypertrigylceridemia in NIDDM. Diabetes 1989:38:364-372.
7. Glueck CJ. Speirs J. Tracy T: Safety and efficacy of combined gemfibrozil-lovastatin therapy for primary dyslipoproteinemia. J Lab Clin Med 1990: i 15:603-609.
8. Illingworth DR. O'Malley JP: The hypolipidemic effects of lovastatin and dofibrate alone and in combination in patients with type 111 hyperlipoproteinemia. Metabolism 1990;39: 403-409.
9. Lintott CJ. Scott RS, Sharpe DN. Nyc F.R. Charleson H. French JK. White HD. Reuben S. Maling TJ, Lewis GR. Sutherland VVF. Robertson MC. Prampton C: Treatment of primary hypercholesterolemia with simvastatin: New Zealand multicenter evaluation. Med J Ausl 1991:155:433-436.
10. Lintott CJ, Scott RS. Nve ER, Robertson ML. Sutherland WHF: The hypolipidaemic effects of pravastatin (CS-514) alone and in combination with bezafibrate or acipimox in patients with primary hypercholestcrolaemia. Diab Nutr Metab 1991:4:117-122.
11. Horsmans Y, Desagcr JP. IIarvengt C: Effects of combined bezafibrate-simvastatin appraised in healthy subjects. J Clin Pharmacol 1992:32: 422-426.
12. Glueck CJ. Oakes N. Speirs J, Tracy T. Lang J: Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 1992;70: 1-9.
13. Wirebaugh SR. Shapiro ML. McIntyre TH, Whitney EJ: A retrospective review of the use of lipid-lowering agents in combination, specifically. gemfibrozil and lovastatin. Pharmacotherapy 1992:12:445-450.
14. Feussncr G. Eichinger M. Ziegler R: The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia. Clin Investigator 1992;70:1027-1035.
15. Deslypere JP: Addition of fibrates to simvastatin therapy in hyperlipidcmic patients. Atherosclerosis 1992:97:S67-S71.
16. Wiklund O. Angelin B. Bergman M. Berglund L, Bondjcrs G. Carlsson A. Linden T. Miettin-en T, Odman B. Olofsson S-O. Saarinen I, Sipi-la R, Sjostrom P. Kron B. Vanhanen H, Wright I: Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993;94:13-20.
17. Da Col PG. Fonda M. Fisicaro M. Tonizzo M. Valenti M. Cattin L: Tolerability and efficacy of combination therapy with simvastatin plus gemfibrozil in type lib refractory familial combined hyperlipidemia. Curr Ther Res 1993:53: 473-483.
18. Yeshurun D, Abukarshin R. Elias N. Lanir A. Naschitz JE: Treatment of severe, resistant familial combined hyperlipidemia with a bezafi-brale-lovastatin combination. Clin Ther 1993: 15:355-363.
19. Athyros VG. Papagcorgiou AA. Hagikonstanti-nou IIJ. Papadopoulos GV. Zamboulis CX. Kontopoulos AG: Combined treatment with pravastatin and gemfibrozil in patients with refractory familial combined hyperlipidemia: A clinical study. Drug Invest 1994;7:134-142.
20. Leitersdorf E. Muratti EN. Eliav O. Meiner V. Eisenberg S. Dann EJ. Schayek E. Peters TK. Stein Y: Efficacy and safely of a combination fiuvastatin-bezafibratc treatment for familial hypercholesterolemia: Comparative analysis to a fluvastatin-cholestyraminc combination. Am J Med 1994:96:401-407.
21. Leitersdorf E. Muratti EN. Eliav O. Peters TK: Efficacy and safety of triple therapy (fluvasta-tin-bczafibratc-cholestyramine) for severe familial hypercholesterolemia. Am J Cardiol 1995;76:84A-88A.
22. Eliav O. Schurr D, Pfister P. Fricdlandcr Y, Ixiterdsorf E: High-dose fluvastatin and beza-fibratc combination treatment for heterozygous familial hypercholesterolemia. Am J Cardiol I995;76:76A-79A.
23. Spence JD. Munoz CE. Hendricks L. Latchin-ian L. Khouri HE: Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995;76:80A-83A.
24. Smit JWA. Jansen GIL. de Bruin TWA. Erkc-lens DW: Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, docs not induce muscle damage. Am J Cardiol 1995:76:126A-128A.
25. Billigham ME: Graft coronary disease: The lesions and the patients. Transplant Proc 1989; 21:3665-3666.
26. Sharpies LD, Caine N, Mullins P. Scott JP. Solis E, English TA. Large SR. Schofield PM. Wallwork J: Risk factor analysis for the major hazards following heart transplantation-rejection. infection, and coronary occlusive disease. Transplantation 1991:52:244-252.
27. Paul LC: Chronic rejection of organ allografts: Magnitude of the problem. Transplant Proc 1993:25:2024-2025.
28. Havty P, Mennander A. Yimaz S. Ustinov J. Raisiinen A. Miettinen A. Lautenschlager I. Lemstrom K. Bruggcman CA, Paavonen T: Towards understanding of the pathophysiology of chronic rejection. Clin Invest 1992:70:780-790.
29. Tobcrt JA: Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62:28J-34J.
30. Kobashigawa JA. Murphy FL. Stevenson LW, Moriguchi JD. Kawata N. Kamjoo P. Brownfield E. Wilmart J, Leonard L. Chek C, Drink-water D. Laks H: Low dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990;82:IV 281-283.
31. Regazzi MB, lacona L, Campana C. Raddato C. Perani LG. Gavazzi A. Vigano M: Altered disposition of pravastatin following concomitant drug therapy with cyclosporine A in transplant recipients. Transplant Proc 1993:25:2732-2734.
32. Aracottir M. Eriksson LO, Thysell H. Karakas JD: Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporine. Nephron 1993:65:410-413.
33. Goldberg RB. Roth D: A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 1995:76: I07A-I09A.
34. Ballantyne CM. Radovancevic B. Farmer JA. Frazier H. Chandler L, Payton-Ross C. Coca-nougher B. Jones PH. Young JB. Gotto AM: Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992:19: 1315-1321.
35. Kuo PC. Kirshcnbaum JM. Gordon J. Laffcl G. Young P. DiSesa VJ. Mudge GH. Vaughan DE: Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am J Cardiol 1989;64:631-635.
36. Vanhaecke J. Clccmput JV. Licrdc JV. Dacncn W, Geest HD: Safety and efficacy of low' dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994:58:42-45.
37. Li PK. Mak TW. Wang AY, Lee YT. Leung CB. Lui SF. Lam CW, Lai KN: The interaction of fluvastatin and cyclosporine A in renal transplant patients. Int J Clin Pharmacol Ther 1995: 33:246-248.
38. Holdaas II. Hartman A. Stenstrom J. Dahl KJ. Borge M. Pfister P: Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995;76:102A-I06A.